博騰股份（股票代碼：300363）成立于2005年，是國內領先的醫藥合同定制研發及生產企業（CDMO），我們為全球藥企、新藥研發機構等提供從臨床早期研究直至藥品上市全生命周期所需的化學原料藥、化學制劑和生物藥的定制研發和生產服務。作為一家國家高新技術企業，博騰為全球知名藥企及藥物研發機構長期提供卓越的端到端CDMO服務，我們的研發、生產和運營機構遍及中國、美國、比利時、瑞士和英國。
博騰致力于成為全球最開放、最創新、最可靠的制藥服務平臺，讓好藥更早惠及大眾。我們擁有領先的研發技術平臺能力、完善的質量管理體系、EHS管理體系和良好的交付記錄，生產基地先后通過NMPA、FDA、PMDA、EMA和WHO權威認證。我們開放近十余年服務全球知名藥企的經驗和國際一流CDMO平臺來積極支持國內藥企的發展，加速新藥上市進程，全面為國內化學和生物制藥、藥物研發機構等提供創新藥CMC服務、MAH委托生產服務、臨床試驗服務、創新藥中間體、原料藥到制劑的定制研發及生產服務和生物基因與細胞CDMO服務。
?
With over 3,000 customer-centric employees, operations and commercial offices across the US, EU and China, Porton Pharma Solutions provides global pharmaceutical companies with innovative, reliable and end-to-end process R&D and manufacturing services across small molecule APIs, dosage forms and biologics.
Our Process Technology Centers and USFDA/EMA/PDMA/NMPA/WHO-inspected Manufacturing Facilities feature state-of-the-art equipment, highly flexible cGMP-compliant production assets, plus over 500 highly skilled scientists and process engineers, all backed by a proven program management system dedicated to seamlessly delivering successful outcomes for your unique project requirements.
We are committed to be the most open, innovative and reliable pharmaceutical service platform in the world and Enabling public’s early access to good medicines. We constantly strive for excellence, and have been recognized through awards by industry forums and global pharmaceutical companies for our process innovation, supply chain performance and compliance with global Quality and EHS standards. By efficiently advancing development and enabling commercialization of multiple high-impact medicines, Porton is proud to have earned the trust of some of the world’s leading and most innovative pharmaceutical companies and many biotechnology companies across the US, EU and Asia.
?
?